Skip to main content
Equibles
PHIO logo

PHIO · Phio Pharmaceuticals Corp.

Track PHIO — free

Use PHIO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.08 -0.03 (-2.70%) At close · Sep 4
Rebalance outlook locked
Going-concern doubt — cleared Aug 6, 2026

The latest filing states the doubt was alleviated.

“The Company has limited cash resources, has incurred recurring operating losses and negative cash flows from its operations since its inception and has not yet recognized any product revenues. These factors have previously raised doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 6, 2026
Market Cap
$12.55M
Shares
11.62M

PHIO metrics

53 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.08
Market cap
$12.55M

Price action

19 metrics
Price change (1W)
-4.4%
Price change (30D)
+1.9%
Price change (3M)
+1.9%
Price change (6M)
-6.9%
Price change (YTD)
+2.9%
Price change (1Y)
-47.6%
Trailing year
Price change (5Y)
—
52-week high
$2.48
52-week low
$0.86
Change from 52-week high
-56.5%
Change from 52-week low
+26.0%
Annualized volatility
82.0%
Beta
1.3
RSI (14D)
46.9
Price vs SMA 50
+1.5%
Price vs SMA 200
-4.0%
Avg volume (3M)
614,587
Relative volume
0.1
Average dollar volume
$583,235

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
11.62M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.0
reciprocal yield 100.4%
FCF yield
-97.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-102.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-18

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$13.47M
Net income (TTM)
−$12.90M
Trailing 12 months
Diluted EPS (TTM)
$-5.85
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-34.72

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+839.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-102.4%
Return on assets
-90.2%
Debt / equity
—
Current ratio
—
EBITDA (TTM)
−$13.47M
Free cash flow (TTM)
−$12.21M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$13.00M
Total assets
$14.31M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$12.20M
Capital expenditures (TTM)
$7,000
R&D (TTM)
$8.53M
SG&A (TTM)
—
Stock compensation (TTM)
$983,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
24
13F filer change QoQ
0
Institutional ownership
5.6%

Short interest

3 metrics
Short interest
2.8%
Latest settlement · 2.6 days to cover
Days to cover
2.6d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
$37,600
Insider-sentiment score
86 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1533040 CUSIP 71880W501 13F (30d) 18 filings 18 filers Visit website